M
Marice B Alcantara
Researcher at Victoria University, Australia
Publications - 9
Citations - 177
Marice B Alcantara is an academic researcher from Victoria University, Australia. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 3 publications receiving 47 citations.
Papers
More filters
Journal ArticleDOI
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
Nazli Dizman,Luis Meza,Paulo Gustavo Bergerot,Marice B Alcantara,Tanya B. Dorff,Yung Lyou,Paul Frankel,Yujie Cui,Valerie Mira,M. Llamas,JoAnn Hsu,Zeynep Zengin,Nicholas Salgia,Sabrina Salgia,Jasnoor Malhotra,Neal Shiv Chawla,Alexander Chehrazi-Raffle,Ramya Muddasani,John D. Gillece,Laurens Reining,Jeff Trent,Motomichi Takahashi,Kentaro Oka,Seiya Higashi,Marcin Kortylewski,Sarah K. Highlander,Sumanta K. Pal +26 more
TL;DR: In this article , a bifidogenic live bacterial product (CBM588) was proposed to augment the response to checkpoint inhibitors through modulation of the gut microbiome, and the results showed that CBM588 appeared to enhance the clinical outcome in patients with metastatic renal cell carcinoma treated with nivolumab-ipilimumab.
Journal ArticleDOI
Regulation of MT1-MMP and MMP-2 by the Serpin PEDF: a Promising New Target for Metastatic Cancer
TL;DR: Understanding the role of PEDF in the regulation of MT1-MMP and MMP-2 as it pertains to cancer control is important in order to understand whether and how such associations provide a novel target for cancer therapy.
Journal ArticleDOI
Pigment epithelium‐derived factor upregulates collagen I and downregulates matrix metalloproteinase 2 in osteosarcoma cells, and colocalises to collagen I and heat shock protein 47 in fetal and adult bone
TL;DR: Pigment epithelium‐derived factor (PEDF) has proven anti-osteosarcoma activity, but the mechanism(s) underpinning its ability to reduce primary bone tumour metastasis is unknown.
Journal ArticleDOI
Pigment epithelium-derived factor as a natural matrix metalloproteinase inhibitor: a comparison with classical matrix metalloproteinase inhibitors used for cancer treatment.
TL;DR: Despite a large body of research being devoted to discovery and development of MMPIs, results have largely not been supportive of this approach to anticancer treatment.
Journal ArticleDOI
Effect of CBM588 in combination with cabozantinib plus nivolumab for patients (pts) with metastatic renal cell carcinoma (mRCC): A randomized clinical trial.
Hedyeh Ebrahimi,Luis Meza,Keehoon Lee,Jasnoor Malhotra,Marice B Alcantara,Zeynep Zengin,Nazli Dizman,Ameish Govindarajan,JoAnn Hsu,Neal Shiv Chawla,Daniela V Castro,Benjamin D. Mercier,Sandy Liu,Alexander Chehrazi-Raffle,Tanya B. Dorff,Paul Frankel,Xiaochen Li,Sumanta K. Pal,Abhishek Tripathi +18 more
TL;DR: In this paper , the authors evaluated the effect of CBM588 on clinical outcomes in patients with mRCC receiving 1st-line (1L) therapy with dual immune checkpoint inhibitors (ICIs).